for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sinovac Biotech Ltd.

SVA.O

Latest Trade

6.47USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

6.25

 - 

6.58

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Sinovac Reports Unaudited First Quarter 2020 Financial Results

June 30 (Reuters) - Sinovac Biotech Ltd <SVA.O>::SINOVAC REPORTS UNAUDITED FIRST QUARTER 2020 FINANCIAL RESULTS.Q1 NON-GAAP LOSS PER SHARE $0.07.Q1 SALES FELL 57.9 PERCENT TO $15.4 MILLION.AS OF MARCH 31, 2020, CASH & CASH EQUIVALENTS INCREASED TO $165.3 MILLION, COMPARED TO $152.7 MILLION AS OF DEC 31, 2019.EXPECTS THAT ITS CURRENT CASH POSITION WILL BE ABLE TO SUPPORT ITS OPERATIONS FOR AT LEAST NEXT 12 MONTHS.

Sinovac Says Positive Prelim Results Of Phase I/II Trials For COVID-19 Vaccine Candidate

June 13 (Reuters) - Sinovac Biotech Ltd <SVA.O>::SINOVAC ANNOUNCES POSITIVE PRELIMINARY RESULTS OF PHASE I/II CLINICAL TRIALS FOR INACTIVATED VACCINE CANDIDATE AGAINST COVID-19.THERE HAVE BEEN NO SEVERE ADVERSE EVENT REPORTED IN EITHER PHASE I OR PHASE II TRIALS.SINOVAC BIOTECH - EXPECTS TO SUBMIT A PHASE II CLINICAL STUDY REPORT AND A PHASE III CLINICAL STUDY PROTOCOL TO CHINA'S NMPA IN NEAR FUTURE.SINOVAC BIOTECH - COMPANY'S COVID-19 VACCINE CANDIDATE, CORONAVAC, SHOWED FAVORABLE IMMUNOGENICITY AND SAFETY PROFILES.

Sinovac Secures $15 Mln In Funding To Accelerate COVID-19 Vaccine Development

May 22 (Reuters) - Sinovac Biotech Ltd <SVA.O>::SINOVAC SECURES $15 MILLION IN FUNDING TO ACCELERATE COVID-19 VACCINE DEVELOPMENT.SINOVAC BIOTECH LTD - ADVANTECH CAPITAL AND VIVO CAPITAL HAVE INVESTED $15 MILLION IN SINOVAC RESEARCH AND DEVELOPMENT.SINOVAC BIOTECH LTD - TWO INVESTORS EACH LOANED $7.5 MILLION IN FORM OF CONVERTIBLE LOAN THAT BEARS INTEREST.SINOVAC BIOTECH - RECEIVED APPROVAL FROM GOVERNMENTAL AUTHORITIES TO CONDUCT BOTH PHASE I & PHASE II HUMAN CLINICAL TRIALS FOR CORONAVAC IN CHINA.SINOVAC BIOTECH - PHASE I CLINICAL TRIAL, WHICH EVALUATES SAFETY, TOLERANCE, PRELIMINARY IMMUNOGENICITY OF CORONAVAC, COMMENCED IN APRIL.

Sinovac Biotech Q3 Non-GAAP Earnings Per Share $0.07

Sinovac Biotech Ltd <SVA.O>::SINOVAC REPORTS UNAUDITED THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $0.07.Q3 EARNINGS PER SHARE $0.06.Q3 SALES ROSE 19.3 PERCENT TO $64.3 MILLION.SINOVAC BIOTECH- DELIVERED SALES GROWTH IN QUARTER DESPITE CHALLENGES FROM MARKET DEMAND FOR SOME OF CO'S VACCINES & LACK OF SUPPLY OF CERTAIN PRODUCTS.EXPECT COMMERCIAL LAUNCHES OF VARICELLA, SIPV, AND QIV IN 2020.EXPECTS VARICELLA VACCINE LICENSE TO BE ISSUED IN EARLY 2020.EXPECTS 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCIN LICENSE TO BE ISSUED IN 2021.EXPECTS QUADRIVALENT INFLUENZA VACCINE PRODUCTION LICENSE TO BE ISSUED IN 2020.EXPECTS SABIN INACTIVATED POLIO VACCINE LICENSE TO BE ISSUED IN 2020.AS OF SEPTEMBER 30, 2019, CASH AND CASH EQUIVALENTS TOTALED $156.7 MILLION.SINOVAC BIOTECH- UNABLE TO ESTIMATE WHEN TRADING WILL RESUME, OR WHETHER NASDAQ WILL TAKE ADDITIONAL ACTION REGARDING TRADING OF CO’S COMMON SHARES.

Sinovac Biotech Q2 Earnings Per Share $0.11

Aug 15 (Reuters) - Sinovac Biotech Ltd <SVA.O>::SINOVAC REPORTS UNAUDITED SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $0.12.Q2 EARNINGS PER SHARE $0.11.Q2 SALES FELL 14.8 PERCENT TO $64 MILLION.

Sinovac Q1 NON-GAAP Earnings Per Share $0.01

July 10 (Reuters) - Sinovac Biotech Ltd <SVA.O>::SINOVAC REPORTS UNAUDITED FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $0.01.Q1 SALES FELL 22.8 PERCENT TO $36.6 MILLION.QTRLY EARNINGS PER SHARE $0.01.1GLOBE’S APPEAL AGAINST ANTIGUA JUDGMENT WILL BE HEARD IN WEEK COMMENCING SEPT 16.

Sinovac Determines Trigger Event Occurred Under Rights Agreement

Feb 22 (Reuters) - Sinovac Biotech Ltd <SVA.O>::SINOVAC DETERMINES TRIGGER EVENT OCCURRED UNDER RIGHTS AGREEMENT.SINOVAC BIOTECH LTD - BOARD AMENDS AND RESTATES RIGHTS AGREEMENT AND DECLARES DIVIDEND DISTRIBUTION OF NEW PREFERRED SHARE PURCHASE RIGHTS.SINOVAC BIOTECH LTD - DETERMINES CERTAIN COLLABORATING SHAREHOLDERS BECAME ACQUIRING PERSONS, VOIDING THEIR PREFERRED SHARE PURCHASE RIGHTS.

Haidian Court In Beijing Issues Injunction Order Restraining Sinovac Chairman Aihua Pan

Dec 12 (Reuters) - Sinovac Biotech Ltd <SVA.O>::HAIDIAN DISTRICT PEOPLE’S COURT IN BEIJING ISSUES INJUNCTION ORDER RESTRAINING AIHUA PAN FROM USING BUSINESS LICENSE AND CORPORATE SEAL OF SINOVAC BEIJING.SINOVAC BIOTECH - COURT ISSUED INTERIM INJUNCTION ORDER RESTRAINING AIHUA PAN FROM USING/AUTHORIZING OTHERS TO USE BUSINESS LICENSE, SEAL OF CO'S UNIT.SINOVAC BIOTECH - COURT ALSO SERVED INJUNCTION ORDER TO CERTAIN BANKS WHERE SINOVAC BEIJING MAINTAINS ACCOUNTS.

Hong Kong High Court Issues Declaratory Orders & Permanent Injunctive Relief In Favor Of Sinovac's Senior Management

Nov 28 (Reuters) - Sinovac Biotech Ltd <SVA.O>::HONG KONG HIGH COURT ISSUES DECLARATORY ORDERS AND PERMANENT INJUNCTIVE RELIEF IN FAVOR OF SINOVAC’S BIOTECH LTD. SENIOR MANAGEMENT.SINOVAC BIOTECH - PERMANENT INJUNCTION RESTRAINS LI PENGFEI, CAO JIANZENG FROM PURPORTING TO ACT AS/TAKE ANY ACTIONS AS DIRECTORS OF SINOVAC HK, UNITS.SINOVAC BIOTECH LTD - LI AND CAO HAVE APPEALED DECISION TO COURT OF APPEALS.

Sinovac Biotech Says Commences Legal Proceedings To Nullify Filings Bearing A Falsified Company Seal And Forged Board Member Signatures

Oct 15 (Reuters) - Sinovac Biotech Ltd <SVA.O>::SINOVAC COMMENCES LEGAL PROCEEDINGS TO NULLIFY FILINGS BEARING A FALSIFIED COMPANY SEAL AND FORGED BOARD MEMBER SIGNATURES.SINOVAC BIOTECH-ALSO PETITIONED IN COURT IN ANTIGUA AND BARBUDA FOR 1GLOBE CAPITAL TO BE RESTRAINED FROM MAKING ATTEMPT TO TAKE CONTROL OF CO.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up